Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases

• Published in: Therapeutic Innovation & Regulatory Science Vol. 56; no. 6; pp. 964 - 975
• Main Authors: Epps, Carla, Bax, Ralph, Croker, Alysha, Green, Dionna, Gropman, Andrea, Klein, Agnes V., Landry, Hannah, Pariser, Anne, Rosenman, Marc, Sakiyama, Michiyo, Sato, Junko, Sen, Kuntal, Stone, Monique, Takeuchi, Fumi, Davis, Jonathan M.
• Format: Journal Article
• Language: English
• Published: Cham Springer Science and Business Media LLC 01.11.2022; Springer International Publishing; Springer Nature B.V
• Subjects: Biological Products; Biopharmaceuticals; Child; Clinical trials; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Data collection; Drug Development; Drug Safety and Pharmacovigilance; Ecosystem; Health policy; Humans; Medicine; Pandemics; Patients; Pediatrics; Pharmacotherapy; Pharmacy; Product development; Public Health; Rare Diseases; Rare Diseases - drug therapy; Review; Rare diseases; Regulatory policy; Pediatric drug development
• ISSN: 2168-4790; 2168-4804; 2168-4804
• DOI: 10.1007/s43441-022-00409-w

The literature thoroughly describes the challenges of pediatric drug development for rare diseases. This includes (1) generating interest from sponsors, (2) small numbers of children affected by a particular disease, (3) difficulties with study design, (4) lack of definitive outcome measures and assessment tools, (5) the need for additional safeguards for children as a vulnerable population, and (6) logistical hurdles to completing trials, especially with the need for longer term follow-up to establish safety and efficacy. There has also been an increasing awareness of the need to engage patients and their families in drug development processes and to address inequities in access to pediatric clinical trials. The year 2020 ushered in yet another challenge—the COVID-19 pandemic. The pediatric drug development ecosystem continues to evolve to meet these challenges. This article will focus on several key factors including recent regulatory approaches and public health policies to facilitate pediatric rare disease drug development, emerging trends in product development (biologics, molecularly targeted therapies), innovations in trial design/endpoints and data collection, and current efforts to increase patient engagement and promote equity. Finally, lessons learned from COVID-19 about building adaptable pediatric rare disease drug development processes will be discussed.